WO2000027887A2 - Cross-linked hyaluronic acids and medical uses thereof - Google Patents
Cross-linked hyaluronic acids and medical uses thereof Download PDFInfo
- Publication number
- WO2000027887A2 WO2000027887A2 PCT/EP1999/008481 EP9908481W WO0027887A2 WO 2000027887 A2 WO2000027887 A2 WO 2000027887A2 EP 9908481 W EP9908481 W EP 9908481W WO 0027887 A2 WO0027887 A2 WO 0027887A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cross
- linked hyaluronic
- hyaluronic acids
- linked
- hyaluronic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
Definitions
- the present invention concerns cross-linked hyaluronic acids, optionally hemisuccinylated or sulphated, the salts thereof with biologically suitable or pharmacologically active cations and the complexes thereof with heavy metals such as copper, zinc and iron.
- the invention also concerns the use of said cross-linked hyaluronic acids, salts and complexes in the medical, pharmaceutical and cosmetic fields.
- Hyaluronic acid is a glycosaminoglycan consisting of disaccharide units of D-glucuronic acid and N-acetylglucosamino-2-acetamido-2-deoxy- D-glucose, connected by ⁇ (1 — > 3) glycoside bonds.
- Natural hyaluronic acid has linear, not cross-linked structure of molecular weight ranging from 50,000 to 8,000,000 D or more, depending on the source and extraction method.
- Hyaluronic acid is present in the synovial liquid, connective tissue and vitreous humor of higher animals, as well as in some bacteria.
- compositions of sodium hyaluronate having various molecular weights are used in human medicine and surgery for instance as substitutes of synovial liquid, tissular antiadhesive agents, substitutes of vitreous humor, artificial tears, agents for the in vivo tissular re-constitution (for instance as extra-cellular matrices for the formation of bone segments, following the colonisation of osteoblasts and subsequent calcification; of connective-dermal tissues, following the colonisation of f ⁇ broblasts), materials for the preparation of artificial skin useful in the treatment of burns or in plastic surgery; coating agents for biocompatible vascular prosthesis, carriers of pharmacologically by active ingredients in controlled-release formulations, etc.
- compositions are used both as bases for moisturising topical formulations and as invasive medical-surgical devices ("filling agents").
- Said cross-linked hyaluronic acids are used as biomaterials for implants, prosthesis and medical devices, as controlled-release matrices for medicaments, as healing, anti-adhesive and dressing agents.
- the sulphation of non cross-linked hyaluronic acid is generally disclosed in US 5013724, mainly concerning the sulphation of heparines, heparans and dermatans for use as antithrombotic and anti-coagulant agents.
- the hemisuccinylation recreation of hyaluronic acid (HY) has never been disclosed.
- An example of this functionalization is disclosed in EP - B- 200574, claiming composite biomaterials consisting of succinylated collagen and chitosan.
- the cross-linking of carboxyalkyl cellulose by means of di - or polyamines is disclosed in EP-A-5661 18 (Kimberly Clark Corp) for the preparation of absorbing materials with HY as cross-linking agent, by heating.
- EP-A-462 426 discloses perforated biocompatible membranes and their uses as artificial skin. Collagen cross-linked with diamines and hyaluronic acid are generically cited as possible materials for said membranes.
- the main chemico-physical and biochemical characteristics of the compounds of the invention are: high biocompatibility; high resistance to enzymatic degradation mainly after sulphation; high capacity to adsorb water, with formation of visco-elastic characteristics dependent on the cross-linking degree as well as on sulphation and/or hemi-succinylation degree; ability to chelate metal ions such as zinc or copper; said derivatives having very good stability.
- the compounds of the invention when sulphated, have a slight anticoagulant activity, whereas it is completely surprising the lack of platelet activation and aggregation (measured as antiadhesive activity; P.R.P. model in rabbits subjected to behavioural stress, described in "Abstract IL 15" — International Conference on Advances in Biomaterials and Tissue Engineering, 14-19 Juin 1998, Capri Italy) both for the cross- linked hyaluronic acid of the invention (with different cross-linking degrees) and for the corresponding sulphate esters; this property is totally absent in the natural hyaluronic acid and esther derivatives.
- the invention concerns new cross-linked hyaluronic acids obtainable by reaction of activated carboxylic groups of native linear hyaluronic acid, of extractive or biosynthetic route, with a polyamine, particularly a linear alkyl diamine.
- the cross-linked hyaluronic acid of the invention is further subjected to sulphation and hemisuccinylation processes.
- the obtained products and their salts or complexes have entirely new properties (for instance, swelling, water motility within the gel; chemotactic activity on endothelial cells, viscoelastic properties).
- Said esterification processes are carried out by known methods (use of reagents pyridine/S0 3 ; chlorosulphonic acid; succinic anhydride, in homogeneous or heterogeneous phase, at pH from 6.5 to 8).
- the polyamine to be used as cross-linking agent according to the invention is preferably a diamine of formula R]NH-A-NHR 2 wherein A is a C 2 - C 10 linear or branched alkylene chain, preferably a C 2 - C 6 chain, optionally substituted by hydroxy, carboxy, halogen, alkoxy and amino groups; a polyoxyalkylene chain [(CH 2 ) n -0-(CH 2 ) n ] m wherein n is 2 or 3, m is an integer from 2 to 10; a C 5 -C 7 cycloalkyl group; an aryl or hetaryl group, preferably 1 , 4 or 1 ,3 disubstituted benzene; R, and R 2 , which are the same or different, are hydrogen, C[-C 6 alkyl, phenyl or benzyl groups.
- A are C 2 - C 6 alkylene or a chain [(CH 2 ) n -0- (CH 2 ) n ] m .
- Ri and R 2 are preferably hydrogen.
- the polyamine is reacted with hyaluronic acid or salts thereof, the carboxylic groups of which have been previously activated.
- the activation may be carried out with conventional methods; for instance, and preferably, those commonly used, in anhydrous aprotic solvent, to form amide bonds in peptide synthesis such as carbonyldiimidazole; carbonyl-triazole; hydroxybenzotriazole; N- hydroxysuccinimide; p-nitrophenol + p-nitrophenyltrifluoro acetate, chloromethylpyridylium iodide; preferably chloromethypyridylium iodide and like; these activators allow the best yields and the highest reproducibility in terms of cross-linking degree.
- the hyaluronic acid is preferably salified with a lipophilic cation, for instance tetralkylammonium or other lipophilic organic bases able to induce the suitable solubility in the polar aprotic solvent such as dimethylformamide, tetrahydrofuran or the like.
- a lipophilic cation for instance tetralkylammonium or other lipophilic organic bases able to induce the suitable solubility in the polar aprotic solvent such as dimethylformamide, tetrahydrofuran or the like.
- the transformation of inorganic salts such as sodium into suitable organic cations may be carried out by well known ion-exchange methods in homogeneous phase or by precipitation of the acid component, its recovery and subsequent salification with the desired organic base.
- the activation reaction of the carboxy groups is usually carried out in homogeneous phase and in anhydrous polar aprotic solvent.
- the cross-linking polyamine is added to the solution of the activated ester in the same anhydrous solvent, keeping the temperature from 0 to 30°C.
- the reaction times range from 1 to 12 hours, depending on the presence of suitable bases such as triethylamine.
- the desired final product is recovered by addition of a different solvent under reduced pressure, followed by conventional work-up.
- the cross-linking degree may be comprised within wide limits and may be adjusted by changing the amount of the carboxy-activating agent, the activation and the cross-linking reactions being practically quantitative.
- the starting hyaluronic acid may be any hyaluronic acid having molecular weight from about 5.000 to 8,000,000 D, preferably from 10.000 to 200,000 D, extracted from conventional sources or obtainable by fermentation of microorganisms of the group Streptococcus or other engineered strains.
- the cross-linked hyaluronic acid of the invention may be subjected to sulphation reaction with a suitable reagent, preferably the pyridine/sulphur trioxide complex in dimethylformamide.
- the reaction is carried out in heterogeneous phase at a temperature of 0-10°C for reaction times ranging from about 0,5 to about 6 hours.
- the obtainable sulphation degree may be comprised within wide limits and may be adjusted by changing the reaction time and the temperature.
- the cross-linked hyaluronic acid of the invention may also be subjected to hemisuccinylation reactions in known conditions (aqueous heterogeneous phase, under strong stirring, addition of solid succinic anhydride in subsequent portions, in ratios from 1 : 1 to 1 :5 by weight; keeping the pH from 7 to 8.5 with alkali, at temperatures ranging from 5 to 30°C).
- the hemisuccinylation degree may be comprised within wide limits depending on the following parameters: reaction time and temperature; stirring speed of the polyphasic system and addition rate of solid succinic anhydride. By keeping said parameters constant, the reaction gives reproducible products.
- the cross-linked hyaluronic acids, optionally sulphated or hemisuccinylated, of the invention show the ability to form complexes with metal ions such as copper, zinc, iron.
- complexes may be easily obtained by dissolving or by dispersing until complete swelling the hyaluronic acid derivative in water and adding under stirring preferably at room temperature, a concentrated solution of an organic or inorganic salt of copper, zinc or iron, for instance CuCl 2 , ZnCl 2 , or Fe 2 (S0 4 ) 3 ; after 12-24 hours under stirring, the complex is recovered by centrifugation or precipitation following change of solvent (e.g. addition of ethanol or acetone) or evaporation under reduced pressure; the recovered crude product is thoroughly washed with distilled water so as to remove the excess ion.
- solvent e.g. addition of ethanol or acetone
- the complexes are then freeze-dried.
- the content of metal ions depends on the used operative conditions: polymer to ion molar ratios, concentration and pH of the solution; reaction times and particularly the cross-linking degree. It may reach the maximum volume of 1 metal ion per disaccharide unit not involved in the cross- linking.
- An important advantage of the invention consists in the possibility of obtaining, by suitably changing the cross-linking degree and/or the sulphation or succinylation degree, hyaluronic acid derivatives in a wide range of different forms, characterised by different properties (such as visco-elasticity, metal ions, ability to form hydrogels, films, sponges, mechanical strength etc.).
- hyaluronic acid derivatives of the invention in several medical and pharmaceutical fields, in the human or veterinary field: 1) as intraarticular substitutes of the synovial liquid for the treatment of osteoarthritic conditions;
- medicaments e.g. antiinflammatories, antibiotics, ⁇ -adrenergic agonists and antagonists, aldose reductase inhibitors, anti-acne, antiallergic, anti-alopecia, antineoplastic, antiglaucoma, anti-itching, anti- psoriasis, anti-seborrhea, anti-ulcer, antiviral agents, growth factors etc.
- medicaments e.g. antiinflammatories, antibiotics, ⁇ -adrenergic agonists and antagonists, aldose reductase inhibitors, anti-acne, antiallergic, anti-alopecia, antineoplastic, antiglaucoma, anti-itching, anti- psoriasis, anti-seborrhea, anti-ulcer, antiviral agents, growth factors etc.
- the medicament may be bound by covalent bonds to the hyaluronic acid matrices, by means of: a) esterification or amidation of COOH not involved in the cross- linking with polyamines, when the medicament is an alcohol or an amine; b) esterification with the free hydroxy groups of hyaluronic acid derivatives when the medicament has free carboxy groups.
- the products under a) may be obtained using the same activation method of the carboxy groups described above in a carefully anhydrous medium or by transesterification.
- Said devices preferably contain suitable drugs such as antibiotics, healing factors.
- vascular prosthesis antiadhesive dressings of blood vessels, artificial heart valves etc.
- biohybrid organs artificial pancreas, liver
- ophthalmic products lacs substitutes, contact lens
- otological products generally of anti-adhesive implants, to be used in abdominal, gynaecological, plastic, orthopaedic, neurological, ophthalmological, thoracic, otorhinolaryngological surgery; of medical device such as stents, catheters, cannulas and the like.
- cross-linked hyaluronic acid and of biomaterials obtained therefrom are known and described, for instance, in WO 97/39788, WO 97/22629, WO 97/18244, WO 97/7833, EP 763754, EP 718312, WO 96/40005, WO 96/33751 , US 5532221 , WO 95/1 165 e EP 320164.
- the use of the cross-linked hyaluronic acids of the invention in cosmetic dermatology is of particular interest, for instance as moisturizing agents, bases of various cosmetological formulations, injectable filling agents etc.
- the formal products obtained from the cross-linked hyaluronic acid derivatives of the invention may by subjected to sterilisation processes (for instance by heating to 120°C or by means of ethylene oxide) without any change in the technological properties, which is of course a further advantage provided by the present invention.
- sterilisation processes for instance by heating to 120°C or by means of ethylene oxide
- TBA salt is then dissolved in 15 ml of anhydrous DMF, under N 2 , and - at 0°C- 0,02 g of cloromethypyridylium Iodide (CMPJ) in 2 ml of anhydrous DFM, are added dropwise to the stored solution of TBA. salt.
- CMPJ cloromethypyridylium Iodide
- d 0.88, in large excess, so as to make cross-linking of the activated carboxy groups easier
- the product was then lyophilised and the residue subjected to analysis.
- hyaluronic acid tributylammonium salt (lxlO '3 mol., with reference to the disaccharide unit) were dissolved under stirring in 30 ml of
- the final product after lyophilisation, shows at the scanning microscope an irregular pattern with smooth zones alternating to spongy zones.
- the cross-linking degree was 0.3 (30% of initially available carboxy groups)
- HY TBA hyaluronic acid tributylammonium salt
- CMPJ chloromethylpyridylium iodide
- a solid, gelly-like product was obtained and thoroughly washed with DMF. After evaporating DMF, the product was swelled in water and washed with ethanol before lyophilization.
- the obtained product had a cross-linking degree of 0.5 and showed at the scanning microscope a grainy aspect interspaced by large meshes. At higher magnitudes, the two morphologies appear identical and show round- shaped protrusions a few microns in diameter.
- the gels were subjected to swelling in PBS and the max swelling ability was evaluated.
- the cross-linked hyaluronic acid derivatives having the characteristics summarised in the following table 1 , were obtained, starting from lxl 0 '3 mol (0.6 g) of hyaluronic acid tributylammonium salt.
- the obtained derivatives had the following properties TABLE 1
- the product was thoroughly washed with ethanol and H 2 0 and then lyophilized.
- the IR spectrum shows, in addition to the bands of the starting product, a peak at 1260 cm “1 and a stronger band at 1025 cm “1 .
- Higher resolution 13C NMR spectrum shows the signals in H 2 0 at 37°C reported in table 2.
- the intensity of the NMR signals at 29.3 and 38.8 ppm (-CH 2 -) and the signal at 172.5 ppm (CONH) confirm a cross-linking degree of about 50%.
- the rheological properties are characterised by dynamic elastic modules G' (2500Pa with 20 mg and 1000 Pa with 10 mg at 10Hz) which are always higher than the dynamic viscous modules G" (600Pa with 20 mg and 150 Pa with 10 mg at 10Hz) and much higher than the corresponding values obtained with non-sulphated HY (13 at 50% - example 5).
- This compound has a thrombin time (TT) higher (61+5") than the control (14.0”) and the corresponding not cross-linked (14.6").
- EXAMPLE 11 Using the same methodology, the sulphated derivatives of 50% cross-linked products according to example 7,8, and 9, have been synthetized.
- EXAMPLE 12 Preparation of complexes of Cu, Zn and Fe.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69903351T DE69903351T3 (en) | 1998-11-11 | 1999-11-08 | NETWORKED HYALURONIC ACID AND ITS MEDICAL USES |
AU26600/00A AU757102B2 (en) | 1998-11-11 | 1999-11-08 | Cross-linked hyaluronic acids and medical uses thereof |
IL14306399A IL143063A0 (en) | 1998-11-11 | 1999-11-08 | Cross-linked hyaluronic acids and medical uses thereof |
US09/830,761 US6831172B1 (en) | 1998-11-11 | 1999-11-08 | Cross-linked hyaluronic acids and medical uses thereof |
JP2000581064A JP2002529550A (en) | 1998-11-11 | 1999-11-08 | Crosslinked hyaluronic acid and its medical use |
BR9915235-5A BR9915235A (en) | 1998-11-11 | 1999-11-08 | cross-linked hyaluronic acids and medical uses thereof |
AT99968778T ATE225371T1 (en) | 1998-11-11 | 1999-11-08 | CROSS-LINKED HYALURONIC ACID AND ITS MEDICAL USES |
HU0104296A HU229668B1 (en) | 1998-11-11 | 1999-11-08 | Cross-linked hyaluronic acids, uses thereof and biological substances containing them |
CA002350667A CA2350667A1 (en) | 1998-11-11 | 1999-11-08 | Cross-linked hyaluronic acids and medical uses thereof |
NZ511306A NZ511306A (en) | 1998-11-11 | 1999-11-08 | Cross-linked hyaluronic acids obtained by reaction of activated carboxy groups of hyaluronic acid (HY) with a polyamine |
DK99968778.3T DK1144459T4 (en) | 1998-11-11 | 1999-11-08 | Crosslinked hyaluronic acids and medical applications thereof |
EP99968778A EP1144459B2 (en) | 1998-11-11 | 1999-11-08 | Cross-linked hyaluronic acids and medical uses thereof |
NO20012315A NO20012315L (en) | 1998-11-11 | 2001-05-10 | Crosslinked hyaluronic acids and medical uses thereof |
HK02102744.3A HK1041011B (en) | 1998-11-11 | 2002-04-11 | Cross-linked hyaluronic acids and medical uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI98A002440 | 1998-11-11 | ||
IT1998MI002440A IT1303735B1 (en) | 1998-11-11 | 1998-11-11 | CROSS-LINKED HYALURONIC ACIDS AND THEIR MEDICAL USES. |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000027887A2 true WO2000027887A2 (en) | 2000-05-18 |
WO2000027887A3 WO2000027887A3 (en) | 2000-11-16 |
Family
ID=11381033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1999/008481 WO2000027887A2 (en) | 1998-11-11 | 1999-11-08 | Cross-linked hyaluronic acids and medical uses thereof |
Country Status (24)
Country | Link |
---|---|
US (1) | US6831172B1 (en) |
EP (1) | EP1144459B2 (en) |
JP (1) | JP2002529550A (en) |
KR (1) | KR100674177B1 (en) |
CN (1) | CN1131241C (en) |
AT (1) | ATE225371T1 (en) |
AU (1) | AU757102B2 (en) |
BR (1) | BR9915235A (en) |
CA (1) | CA2350667A1 (en) |
CZ (1) | CZ296842B6 (en) |
DE (1) | DE69903351T3 (en) |
DK (1) | DK1144459T4 (en) |
ES (1) | ES2184521T5 (en) |
HK (1) | HK1041011B (en) |
HU (1) | HU229668B1 (en) |
IL (1) | IL143063A0 (en) |
IT (1) | IT1303735B1 (en) |
NO (1) | NO20012315L (en) |
NZ (1) | NZ511306A (en) |
PT (1) | PT1144459E (en) |
RU (1) | RU2230752C2 (en) |
TR (1) | TR200101324T2 (en) |
WO (1) | WO2000027887A2 (en) |
ZA (1) | ZA200103799B (en) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100375299B1 (en) * | 2000-10-10 | 2003-03-10 | 주식회사 엘지생명과학 | Crosslinked derivatives of hyaluronic acid by amide formation and their preparation methods |
EP1357936A1 (en) * | 2001-01-16 | 2003-11-05 | The Board Of Regents Of The University Of Michigan | BIOCATALYTIC AND BIOMIMETIC GENERATION OF NITRIC OXIDE i IN SITU /i AT SUBSTRATE/BLOOD INTERFACES |
WO2004011503A1 (en) * | 2002-07-26 | 2004-02-05 | Lg Life Sciences Ltd. | Hyaluronic acid derivative gel and method for preparing the same |
WO2006069578A1 (en) * | 2004-12-30 | 2006-07-06 | Novozymes Biopolymer A/S | Hyaluronic acid linked with a polymer of an alpha hydroxy acid |
WO2006092233A1 (en) * | 2005-03-02 | 2006-09-08 | Fidia Farmaceutici S.P.A. | Amide derivatives of hyaluronic acid in osteoarthrosis |
US7128904B2 (en) | 2001-01-16 | 2006-10-31 | The Regents Of The University Of Michigan | Material containing metal ion ligand complex producing nitric oxide in contact with blood |
US7335383B2 (en) | 2001-01-16 | 2008-02-26 | The Regents Of The University Of Michigan | Generation of nitric oxide in vivo from nitrite, nitrate or nitrosothiols endogenous in blood |
FR2909285A1 (en) * | 2006-12-01 | 2008-06-06 | Anteis Sa | Use of an injectable or implantable antiadhesive antifibrotic gel based on a crosslinked natural or synthetic polymer for treating glaucoma or surgical wounds |
WO2008068297A1 (en) * | 2006-12-06 | 2008-06-12 | Pierre Fabre Dermo-Cosmetique | Hyaluronic acid gel for intradermal injection |
US7884087B1 (en) | 1998-07-06 | 2011-02-08 | Fidia Farmaceutici S.P.A. | Amides of hyaluronic acid the derivatives thereof and a process for their preparation |
WO2011080450A1 (en) * | 2010-01-04 | 2011-07-07 | L'oreal | Cosmetic or dermatological composition, cosmetic treatment method, and hyaluronic acid derivative |
US8137685B2 (en) | 2003-10-29 | 2012-03-20 | Teijin Limited | Hyaluronic acid compound, hydrogel thereof and joint treating material |
US8143391B2 (en) * | 2004-09-07 | 2012-03-27 | Chugai Seiyaku Kabushiki Kaisha | Process for producing water-soluble hyaluronic acid modification |
CN102574930A (en) * | 2009-09-28 | 2012-07-11 | 泰尔茂株式会社 | Active esterified polysaccharide and method for producing same |
US8481080B2 (en) | 2004-11-24 | 2013-07-09 | Novozymes Biopolymer A/S | Method of cross-linking hyaluronic acid with divinulsulfone |
ITUD20130119A1 (en) * | 2013-09-12 | 2015-03-13 | Limacorporate Spa | BIOCOMPATIBLE IDROGEL FOR BIOMEDICAL OR PHARMACEUTICAL USE, INTERMEDIATE POLYMER TO REALIZE THE BIOCOMPATIBLE IDROGEL AND ITS APPLICATION METHOD |
WO2015073919A1 (en) * | 2013-11-14 | 2015-05-21 | University Medical Pharmaceuticals Corporation | Microneedles for therapeutic agent delivery with improved mechanical properties |
US9907739B2 (en) | 2012-10-24 | 2018-03-06 | Teoxane | Dermal injectable sterile composition |
WO2018055002A1 (en) * | 2016-09-21 | 2018-03-29 | Nestlé Skin Health Sa | Hyaluronic acid gel with a divalent zinc cation |
WO2019001784A1 (en) | 2017-06-28 | 2019-01-03 | Nestlé Skin Health Sa | Hyaluronic acid gel with a divalent cation |
CN110123741A (en) * | 2019-06-24 | 2019-08-16 | 中国医学科学院基础医学研究所 | A kind of iron cross-linked-hyaluronic acid nanogel, preparation method and purposes |
US11020512B2 (en) | 2008-08-04 | 2021-06-01 | Allergan Industrie, Sas | Hyaluronic acid-based gels including lidocaine |
US11642415B2 (en) | 2017-03-22 | 2023-05-09 | Ascendis Pharma A/S | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITPD980037A1 (en) * | 1998-02-25 | 1999-08-25 | Fidia Advanced Biopolymers Srl | SULFATED HYALURONIC ACID AND ITS DERIVATIVES COVALENTLY LINKED TO SYNTHETIC POLYMERS FOR THE PREPARATION OF BIOMATERIALS AND FOR COATING |
US7068729B2 (en) | 2001-12-21 | 2006-06-27 | Digital Fountain, Inc. | Multi-stage code generator and decoder for communication systems |
US6307487B1 (en) | 1998-09-23 | 2001-10-23 | Digital Fountain, Inc. | Information additive code generator and decoder for communication systems |
IT1303738B1 (en) * | 1998-11-11 | 2001-02-23 | Aquisitio S P A | CARBOXYLATE POLYSACCHARIDE CROSS-LINKING PROCESS. |
DE60036915T2 (en) | 1999-01-13 | 2008-08-07 | Alchemia Oncology Pty Ltd., Hawthorn | USE OF HYALURONAN FOR THE MANUFACTURE OF A MEDICAMENT FOR INCREASING THE EFFICACY OF CYTOTOXIC DRUGS |
KR100338179B1 (en) * | 2000-05-08 | 2002-05-24 | 김범철 | Graft copolymer for ophthalmic drug delivery and process for preparing thereof |
AUPQ879500A0 (en) * | 2000-07-14 | 2000-08-10 | Meditech Research Limited | Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease |
US9066919B2 (en) * | 2000-07-14 | 2015-06-30 | Alchemia Oncology Pty Limited | Hyaluronan as a chemo-sensitizer in the treatment of cancer |
WO2003018062A1 (en) * | 2001-08-27 | 2003-03-06 | Meditech Research Limited | Improved therapeutic protocols |
US9240810B2 (en) | 2002-06-11 | 2016-01-19 | Digital Fountain, Inc. | Systems and processes for decoding chain reaction codes through inactivation |
EP2355360B1 (en) | 2002-10-05 | 2020-08-05 | QUALCOMM Incorporated | Systematic encoding and decoding of chain reaction codes |
WO2004037120A2 (en) * | 2002-10-25 | 2004-05-06 | Essentia Biosystems, Inc. | Implantable medical devices using zinc |
FR2850282B1 (en) | 2003-01-27 | 2007-04-06 | Jerome Asius | INJECTABLE IMPLANT BASED ON CERAMIC FOR THE FILLING OF WRINKLES, CUTANEOUS DEPRESSIONS AND SCARS, AND ITS PREPARATION |
EP1595892A4 (en) * | 2003-02-21 | 2007-06-20 | Terumo Corp | Crosslinkable polysaccharide derivative, process for producing the same, crosslinkable polysaccharide composition and medical treatment material |
JP2004262777A (en) * | 2003-02-27 | 2004-09-24 | Shiseido Co Ltd | Acetylated hyaluronic acid-containing ocular medicinal preparation |
AU2003228014B2 (en) * | 2003-04-04 | 2009-11-05 | Nobil Bio Ricerche S.R.L. | Vascular stent |
CN1954501B (en) | 2003-10-06 | 2010-06-16 | 数字方敦股份有限公司 | Method for receving data transmitted from a source by communication channel |
US20090148527A1 (en) * | 2007-12-07 | 2009-06-11 | Robinson Michael R | Intraocular formulation |
EP1743431A4 (en) | 2004-05-07 | 2007-05-02 | Digital Fountain Inc | File download and streaming system |
ITMI20041373A1 (en) | 2004-07-09 | 2004-10-09 | Lima Lto S P A | N-METHYL-CARBOXYMETHYLCELLULOSE ACID ALGINIC OR CARBOXYMETALAMIDE |
JP4875988B2 (en) * | 2004-11-15 | 2012-02-15 | 株式会社 資生堂 | Method for producing crosslinked hyaluronic acid gel |
TW200643033A (en) * | 2005-03-08 | 2006-12-16 | Chugai Pharmaceutical Co Ltd | Conjugate of water-soluble modified hyaluronic acid and glp-1 analogue |
US7676735B2 (en) | 2005-06-10 | 2010-03-09 | Digital Fountain Inc. | Forward error-correcting (FEC) coding and streaming |
CA2616607C (en) | 2005-07-27 | 2015-06-02 | Alchemia Oncology Pty Limited | Therapeutic protocols using hyaluronan |
AU2006289651B2 (en) | 2005-09-07 | 2012-07-26 | Alchemia Oncology Pty Limited | Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment |
US7879818B2 (en) * | 2005-12-23 | 2011-02-01 | Janos Borbely | Hyaluronic acid-based cross-linked nanoparticles |
KR100737954B1 (en) * | 2006-01-03 | 2007-07-13 | 고려대학교 산학협력단 | Injectable hydrogels based on hyaluonic acid for tissue regeneration |
US9136983B2 (en) | 2006-02-13 | 2015-09-15 | Digital Fountain, Inc. | Streaming and buffering using variable FEC overhead and protection periods |
US9270414B2 (en) | 2006-02-21 | 2016-02-23 | Digital Fountain, Inc. | Multiple-field based code generator and decoder for communications systems |
US20100273734A1 (en) * | 2006-02-28 | 2010-10-28 | Novozymes Biopolymer A/S | Derivatives of Hyaluronic Acids |
US7674781B2 (en) * | 2006-04-28 | 2010-03-09 | Heather Sheardown | Hyaluronic acid-retaining polymers |
US7971129B2 (en) | 2006-05-10 | 2011-06-28 | Digital Fountain, Inc. | Code generator and decoder for communications systems operating using hybrid codes to allow for multiple efficient users of the communications systems |
US9178535B2 (en) | 2006-06-09 | 2015-11-03 | Digital Fountain, Inc. | Dynamic stream interleaving and sub-stream based delivery |
US9380096B2 (en) | 2006-06-09 | 2016-06-28 | Qualcomm Incorporated | Enhanced block-request streaming system for handling low-latency streaming |
US9386064B2 (en) | 2006-06-09 | 2016-07-05 | Qualcomm Incorporated | Enhanced block-request streaming using URL templates and construction rules |
US9209934B2 (en) | 2006-06-09 | 2015-12-08 | Qualcomm Incorporated | Enhanced block-request streaming using cooperative parallel HTTP and forward error correction |
US9419749B2 (en) | 2009-08-19 | 2016-08-16 | Qualcomm Incorporated | Methods and apparatus employing FEC codes with permanent inactivation of symbols for encoding and decoding processes |
US9432433B2 (en) | 2006-06-09 | 2016-08-30 | Qualcomm Incorporated | Enhanced block-request streaming system using signaling or block creation |
EP2049572A1 (en) * | 2006-08-04 | 2009-04-22 | Novozymes Biopolymer A/S | Branched hyaluronic acid and method of manufacture |
US20080070993A1 (en) * | 2006-09-07 | 2008-03-20 | Janos Borbely | Additives for cosmetic products and the like |
JP2008255061A (en) * | 2007-04-06 | 2008-10-23 | Shiseido Co Ltd | Soluble cross-linked hyaluronic acid-containing ophthalmic composition |
WO2009012367A1 (en) * | 2007-07-18 | 2009-01-22 | Aesthetic Science | Composition and method of use for soft tissue augmentation/drug delivery |
EP2178908B1 (en) * | 2007-08-15 | 2013-07-10 | Metamorefix | Peptides and pharmaceutical compositions for treating connective tissue |
WO2009036378A1 (en) | 2007-09-12 | 2009-03-19 | Digital Fountain, Inc. | Generating and communicating source identification information to enable reliable communications |
CN102177180A (en) | 2008-04-04 | 2011-09-07 | 犹他州大学研究基金会 | Alkylated sem-synthetic glycosaminoglycosan ethers, and methods for making and using thereof |
WO2009148985A2 (en) * | 2008-06-03 | 2009-12-10 | E. I. Du Pont De Nemours And Company | A tissue coating for preventing undesired tissue-to-tissue adhesions |
EP2311883A1 (en) * | 2008-08-05 | 2011-04-20 | Teijin Limited | Hydrogel |
US20100104654A1 (en) | 2008-10-27 | 2010-04-29 | Allergan, Inc. | Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof |
FR2938187B1 (en) * | 2008-11-07 | 2012-08-17 | Anteis Sa | INJECTABLE COMPOSITION BASED ON HYALURONIC ACID OR ONE OF ITS HEAT-STERILIZED SALTS, POLYOLS AND LIDOCAINE |
US9281847B2 (en) | 2009-02-27 | 2016-03-08 | Qualcomm Incorporated | Mobile reception of digital video broadcasting—terrestrial services |
US9288010B2 (en) | 2009-08-19 | 2016-03-15 | Qualcomm Incorporated | Universal file delivery methods for providing unequal error protection and bundled file delivery services |
IT1395392B1 (en) * | 2009-08-27 | 2012-09-14 | Fidia Farmaceutici | VISCOELASTIC FROSTS LIKE NEW FILLERS |
US9917874B2 (en) | 2009-09-22 | 2018-03-13 | Qualcomm Incorporated | Enhanced block-request streaming using block partitioning or request controls for improved client-side handling |
US20110280311A1 (en) | 2010-05-13 | 2011-11-17 | Qualcomm Incorporated | One-stream coding for asymmetric stereo video |
JP2013530785A (en) * | 2010-07-12 | 2013-08-01 | シン・プーン・ファーマシューティカル・カンパニー・リミテッド | Filling composition for tissue augmentation |
US9596447B2 (en) | 2010-07-21 | 2017-03-14 | Qualcomm Incorporated | Providing frame packing type information for video coding |
US9456015B2 (en) | 2010-08-10 | 2016-09-27 | Qualcomm Incorporated | Representation groups for network streaming of coded multimedia data |
US8958375B2 (en) | 2011-02-11 | 2015-02-17 | Qualcomm Incorporated | Framing for an improved radio link protocol including FEC |
US9270299B2 (en) | 2011-02-11 | 2016-02-23 | Qualcomm Incorporated | Encoding and decoding using elastic codes with flexible source block mapping |
JP6062917B2 (en) | 2011-03-23 | 2017-01-18 | ザ ユニバーシティ オブ ユタ リサーチ ファウンデイション | Method of treating and preventing urological inflammation |
RU2477155C2 (en) * | 2011-04-27 | 2013-03-10 | Закрытое акционерное общество "Патент-Фарм" | Method of treating androgenetic alopecia |
US9253233B2 (en) | 2011-08-31 | 2016-02-02 | Qualcomm Incorporated | Switch signaling methods providing improved switching between representations for adaptive HTTP streaming |
US9843844B2 (en) | 2011-10-05 | 2017-12-12 | Qualcomm Incorporated | Network streaming of media data |
CZ2012136A3 (en) * | 2012-02-28 | 2013-06-05 | Contipro Biotech S.R.O. | Derivatives based on hyaluronic acid capable of forming hydrogels, process of their preparation, hydrogels based on these derivatives, process of their preparation and use |
US9294226B2 (en) | 2012-03-26 | 2016-03-22 | Qualcomm Incorporated | Universal object delivery and template-based file delivery |
FR3005056B1 (en) * | 2013-04-24 | 2016-04-01 | Ayawane | HYDROGEL BASED ON NATIVE AND / OR FUNCTIONALIZED POLYSACCHARIDES, CO-RETICULATED PHOSPHATES |
JP6479783B2 (en) * | 2013-06-28 | 2019-03-06 | ガルデルマ エス.エー. | Method for preparing a crosslinked hyaluronic acid product |
US9421198B2 (en) | 2013-07-30 | 2016-08-23 | Teoxane | Composition comprising hyaluronic acid and mepivacaine |
US10294195B2 (en) | 2014-01-31 | 2019-05-21 | Seikagaku Corporation | Diamine crosslinking agents, crosslinked acidic polysaccharides and medical materials |
HUE050124T2 (en) | 2015-12-29 | 2020-11-30 | Galderma Sa | Method for deacetylation of biopolymers |
WO2018053111A1 (en) | 2016-09-15 | 2018-03-22 | University Of Utah Research Foundation | In situ gelling compositions for the treatment or prevention of inflammation and tissue damage |
CN107469090B (en) * | 2017-08-15 | 2020-05-12 | 浙江大学 | Nano-carrier capable of carrying anti-tumor drug and nucleic acid drug together and anti-tumor drug nano-preparation |
CN111228653A (en) | 2018-11-13 | 2020-06-05 | 格莱科米拉治疗公司 | Method for enhancing cancer treatment with ionizing radiation |
EP3659632A1 (en) | 2018-11-29 | 2020-06-03 | Nestlé Skin Health SA | Post-crosslinking partial degradation of amide crosslinked hydrogels |
KR20220005465A (en) * | 2019-04-19 | 2022-01-13 | 조인테라퓨틱스 에스알엘 | Cross-linked polymers of functionalized hyaluronic acid and their use in the treatment of inflammatory conditions |
CN110684211B (en) * | 2019-10-14 | 2022-07-12 | 宁夏妙朗生物科技有限公司 | Method for preparing cross-linked dextran gel resistant to hydrolysis by alpha-glucosidase |
CA3160575A1 (en) | 2019-12-02 | 2021-06-10 | Johan Olsson | High molecular weight esthetic compositions |
WO2022109050A1 (en) * | 2020-11-18 | 2022-05-27 | Bexson Biomedical, Inc. | Complexing agent salt formulations of pharmaceutical compounds |
JP2023551145A (en) | 2020-11-18 | 2023-12-07 | ベクソン バイオメディカル,インク. | Complexing agent salt formulations of pharmaceutical compounds |
WO2023148619A1 (en) | 2022-02-01 | 2023-08-10 | Galderma Holding SA | Methods of producing crosslinked hyaluronic acid hydrogels |
CN114561046B (en) * | 2022-02-28 | 2023-10-27 | 江南大学 | Guanidine hyaluronic acid type antibacterial hydrogel and preparation method and application thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4851521A (en) * | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
IT1198449B (en) * | 1986-10-13 | 1988-12-21 | F I D I Farmaceutici Italiani | ESTERS OF POLYVALENT ALCOHOLS OF HYALURONIC ACID |
JPH05508631A (en) * | 1990-05-04 | 1993-12-02 | イッサム・リサーチ・デベロップメント・カンパニー・オブ・ザ・ヒーブリュー・ユニバーシティー・オブ・エルサレム | Colonic drug delivery system |
WO1993003776A1 (en) * | 1991-08-16 | 1993-03-04 | Galin Miles A | Medicament coated refractive anterior chamber ocular implant |
IT1254170B (en) * | 1991-12-18 | 1995-09-11 | Mini Ricerca Scient Tecnolog | COMPOSITE MEMBRANES FOR GUIDED REGENERATION OF FABRICS |
CA2076732C (en) * | 1992-04-17 | 2006-05-09 | Kimberly-Clark Worldwide, Inc. | Modified polysaccharides having improved absorbent properties and process for the preparation thereof |
JPH06154596A (en) * | 1992-11-18 | 1994-06-03 | Sanyo Chem Ind Ltd | Salt resistant absorbent and manufacture of the same |
US5616568A (en) * | 1993-11-30 | 1997-04-01 | The Research Foundation Of State University Of New York | Functionalized derivatives of hyaluronic acid |
JPH0959303A (en) * | 1995-08-22 | 1997-03-04 | Shiseido Co Ltd | Biocompatible hyaluronic acid gel and its application |
FR2752843B1 (en) * | 1996-08-30 | 1998-10-16 | Sod Conseils Rech Applic | CROSSLINKED COPOLYMERS BASED ON POLYCARBOXYLIC POLYMERS AND THEIR USE AS SUPPORTS OF PHARMACEUTICAL COMPOSITIONS |
IT1303738B1 (en) * | 1998-11-11 | 2001-02-23 | Aquisitio S P A | CARBOXYLATE POLYSACCHARIDE CROSS-LINKING PROCESS. |
-
1998
- 1998-11-11 IT IT1998MI002440A patent/IT1303735B1/en active
-
1999
- 1999-11-08 HU HU0104296A patent/HU229668B1/en not_active IP Right Cessation
- 1999-11-08 IL IL14306399A patent/IL143063A0/en not_active IP Right Cessation
- 1999-11-08 CN CN99813143A patent/CN1131241C/en not_active Expired - Fee Related
- 1999-11-08 NZ NZ511306A patent/NZ511306A/en not_active IP Right Cessation
- 1999-11-08 KR KR1020017005929A patent/KR100674177B1/en not_active IP Right Cessation
- 1999-11-08 CA CA002350667A patent/CA2350667A1/en not_active Abandoned
- 1999-11-08 ES ES99968778T patent/ES2184521T5/en not_active Expired - Lifetime
- 1999-11-08 JP JP2000581064A patent/JP2002529550A/en active Pending
- 1999-11-08 US US09/830,761 patent/US6831172B1/en not_active Expired - Lifetime
- 1999-11-08 DK DK99968778.3T patent/DK1144459T4/en active
- 1999-11-08 CZ CZ20011650A patent/CZ296842B6/en not_active IP Right Cessation
- 1999-11-08 TR TR2001/01324T patent/TR200101324T2/en unknown
- 1999-11-08 PT PT99968778T patent/PT1144459E/en unknown
- 1999-11-08 BR BR9915235-5A patent/BR9915235A/en not_active IP Right Cessation
- 1999-11-08 WO PCT/EP1999/008481 patent/WO2000027887A2/en active IP Right Grant
- 1999-11-08 RU RU2001112488/04A patent/RU2230752C2/en not_active IP Right Cessation
- 1999-11-08 AU AU26600/00A patent/AU757102B2/en not_active Ceased
- 1999-11-08 DE DE69903351T patent/DE69903351T3/en not_active Expired - Lifetime
- 1999-11-08 AT AT99968778T patent/ATE225371T1/en active
- 1999-11-08 EP EP99968778A patent/EP1144459B2/en not_active Expired - Lifetime
-
2001
- 2001-05-10 NO NO20012315A patent/NO20012315L/en not_active Application Discontinuation
- 2001-05-10 ZA ZA200103799A patent/ZA200103799B/en unknown
-
2002
- 2002-04-11 HK HK02102744.3A patent/HK1041011B/en not_active IP Right Cessation
Non-Patent Citations (1)
Title |
---|
None |
Cited By (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7884087B1 (en) | 1998-07-06 | 2011-02-08 | Fidia Farmaceutici S.P.A. | Amides of hyaluronic acid the derivatives thereof and a process for their preparation |
EP1328552A4 (en) * | 2000-10-10 | 2005-11-09 | Lg Life Sciences Ltd | Crosslinked amide derivatives of hyaluronic acid and manufacturing method thereof |
EP1328552A1 (en) * | 2000-10-10 | 2003-07-23 | LG Life Sciences Ltd. | Crosslinked amide derivatives of hyaluronic acid and manufacturing method thereof |
KR100375299B1 (en) * | 2000-10-10 | 2003-03-10 | 주식회사 엘지생명과학 | Crosslinked derivatives of hyaluronic acid by amide formation and their preparation methods |
US7128904B2 (en) | 2001-01-16 | 2006-10-31 | The Regents Of The University Of Michigan | Material containing metal ion ligand complex producing nitric oxide in contact with blood |
EP1357936A4 (en) * | 2001-01-16 | 2005-08-10 | Univ Michigan | BIOCATALYTIC AND BIOMIMETIC GENERATION OF NITRIC OXIDE i IN SITU /i AT SUBSTRATE/BLOOD INTERFACES |
US7335383B2 (en) | 2001-01-16 | 2008-02-26 | The Regents Of The University Of Michigan | Generation of nitric oxide in vivo from nitrite, nitrate or nitrosothiols endogenous in blood |
US8034384B2 (en) | 2001-01-16 | 2011-10-11 | The Regents Of The University Of Michigan | Method of increasing biocompatibility of medical device by generating nitric oxide |
EP1357936A1 (en) * | 2001-01-16 | 2003-11-05 | The Board Of Regents Of The University Of Michigan | BIOCATALYTIC AND BIOMIMETIC GENERATION OF NITRIC OXIDE i IN SITU /i AT SUBSTRATE/BLOOD INTERFACES |
US7763283B2 (en) | 2001-01-16 | 2010-07-27 | The Regents Of The University Of Michigan | Nitric oxide (NO) releasing material |
US8168423B2 (en) | 2001-01-16 | 2012-05-01 | The Regents Of The University Of Michigan | Device for detecting nitrosothiol content in solution |
WO2004011503A1 (en) * | 2002-07-26 | 2004-02-05 | Lg Life Sciences Ltd. | Hyaluronic acid derivative gel and method for preparing the same |
US8137685B2 (en) | 2003-10-29 | 2012-03-20 | Teijin Limited | Hyaluronic acid compound, hydrogel thereof and joint treating material |
US9394379B2 (en) | 2004-09-07 | 2016-07-19 | Chugai Seiyaku Kabushiki Kaisha | Process for producing water-soluble hyaluronic acid modification |
US8143391B2 (en) * | 2004-09-07 | 2012-03-27 | Chugai Seiyaku Kabushiki Kaisha | Process for producing water-soluble hyaluronic acid modification |
US8481080B2 (en) | 2004-11-24 | 2013-07-09 | Novozymes Biopolymer A/S | Method of cross-linking hyaluronic acid with divinulsulfone |
WO2006069578A1 (en) * | 2004-12-30 | 2006-07-06 | Novozymes Biopolymer A/S | Hyaluronic acid linked with a polymer of an alpha hydroxy acid |
AU2006220034B2 (en) * | 2005-03-02 | 2010-11-18 | Fidia Farmaceutici S.P.A. | Amide derivatives of hyaluronic acid in osteoarthrosis |
EP2457574A1 (en) * | 2005-03-02 | 2012-05-30 | Fidia Farmaceutici S.p.A. | Amide derivatives of hyaluronic acid in osteoarthrosis |
US7863256B2 (en) | 2005-03-02 | 2011-01-04 | Fidia Farmaceutici S.P.A. | Amide derivatives of hyaluronic acid in osteoarthrosis |
WO2006092233A1 (en) * | 2005-03-02 | 2006-09-08 | Fidia Farmaceutici S.P.A. | Amide derivatives of hyaluronic acid in osteoarthrosis |
FR2909285A1 (en) * | 2006-12-01 | 2008-06-06 | Anteis Sa | Use of an injectable or implantable antiadhesive antifibrotic gel based on a crosslinked natural or synthetic polymer for treating glaucoma or surgical wounds |
WO2008068297A1 (en) * | 2006-12-06 | 2008-06-12 | Pierre Fabre Dermo-Cosmetique | Hyaluronic acid gel for intradermal injection |
FR2909560A1 (en) * | 2006-12-06 | 2008-06-13 | Fabre Pierre Dermo Cosmetique | HYALURONIC ACID GEL FOR INTRADERMAL INJECTION |
AU2007328917B2 (en) * | 2006-12-06 | 2012-08-02 | Merz Pharma Gmbh & Co. Kgaa | Hyaluronic acid gel for intradermal injection |
EP2152329B1 (en) | 2006-12-06 | 2017-02-15 | Merz Pharma GmbH & Co. KGaA | Hyaluronic acid gel for intradermal injection |
EP2489374A1 (en) * | 2006-12-06 | 2012-08-22 | Pierre Fabre Dermo-Cosmétique | Hyaluronic acid gel for intradermal injection |
CN101594892A (en) * | 2006-12-06 | 2009-12-02 | 皮埃尔·法布尔皮肤化妆品公司 | Hyaluronic acid gel for intradermal injection |
US11020512B2 (en) | 2008-08-04 | 2021-06-01 | Allergan Industrie, Sas | Hyaluronic acid-based gels including lidocaine |
US11173232B2 (en) | 2008-08-04 | 2021-11-16 | Allergan Industrie, Sas | Hyaluronic acid-based gels including lidocaine |
EP2484699A1 (en) * | 2009-09-28 | 2012-08-08 | Terumo Kabushiki Kaisha | Active esterified polysaccharide and method for producing same |
EP2484699A4 (en) * | 2009-09-28 | 2013-07-24 | Terumo Corp | Active esterified polysaccharide and method for producing same |
CN102574930A (en) * | 2009-09-28 | 2012-07-11 | 泰尔茂株式会社 | Active esterified polysaccharide and method for producing same |
US8722025B2 (en) | 2010-01-04 | 2014-05-13 | L'oreal | Cosmetic dermatological composition, cosmetic treatment method, and hyaluronic acid derivative |
FR2954945A1 (en) * | 2010-01-04 | 2011-07-08 | Oreal | COSMETIC OR DERMATOLOGICAL COMPOSITION, COSMETIC PROCESSING METHOD, AND HYALURONIC ACID DERIVATIVE |
WO2011080450A1 (en) * | 2010-01-04 | 2011-07-07 | L'oreal | Cosmetic or dermatological composition, cosmetic treatment method, and hyaluronic acid derivative |
US10307362B2 (en) | 2012-10-24 | 2019-06-04 | Teoxane SA | Dermal injectable sterile composition |
US9907739B2 (en) | 2012-10-24 | 2018-03-06 | Teoxane | Dermal injectable sterile composition |
ITUD20130119A1 (en) * | 2013-09-12 | 2015-03-13 | Limacorporate Spa | BIOCOMPATIBLE IDROGEL FOR BIOMEDICAL OR PHARMACEUTICAL USE, INTERMEDIATE POLYMER TO REALIZE THE BIOCOMPATIBLE IDROGEL AND ITS APPLICATION METHOD |
WO2015073919A1 (en) * | 2013-11-14 | 2015-05-21 | University Medical Pharmaceuticals Corporation | Microneedles for therapeutic agent delivery with improved mechanical properties |
US10898613B2 (en) | 2016-09-21 | 2021-01-26 | Nestlé Skin Health Sa | Hyaluronic acid gel with a divalent zinc cation |
WO2018055002A1 (en) * | 2016-09-21 | 2018-03-29 | Nestlé Skin Health Sa | Hyaluronic acid gel with a divalent zinc cation |
US11642415B2 (en) | 2017-03-22 | 2023-05-09 | Ascendis Pharma A/S | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods |
WO2019001784A1 (en) | 2017-06-28 | 2019-01-03 | Nestlé Skin Health Sa | Hyaluronic acid gel with a divalent cation |
CN110123741A (en) * | 2019-06-24 | 2019-08-16 | 中国医学科学院基础医学研究所 | A kind of iron cross-linked-hyaluronic acid nanogel, preparation method and purposes |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1144459B1 (en) | Cross-linked hyaluronic acids and medical uses thereof | |
AU738788B2 (en) | N-sulphated hyaluronic acid compounds, derivatives thereof and a process for their preparation | |
DE69925733T2 (en) | HYALURONIC ACID AMIDES AND THEIR DERIVATIVES AND A METHOD FOR THE PRODUCTION THEREOF | |
AU2005257078B2 (en) | Hydrogels of hyaluronic acid and alpha, beta-polyaspartylhydrazide and their biomedical and pharmaceutical uses | |
EP1753787B1 (en) | Method of covalently linking hyaluronan and chitosan | |
US5652347A (en) | Method for making functionalized derivatives of hyaluronic acid | |
US20050250939A1 (en) | Process for the production of multiple cross-linked hyaluronic acid derivatives | |
EP2318062A2 (en) | New biomaterials, their preparation by electrospinning and their use in the biomedical and surgical field | |
MXPA01004712A (en) | Cross-linked hyaluronic acids and medical uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99813143.1 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 511306 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2001/00377/DE Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999968778 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/004712 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2350667 Country of ref document: CA Ref document number: 2350667 Country of ref document: CA Kind code of ref document: A Ref document number: 2000 581064 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2001-1650 Country of ref document: CZ Ref document number: 2001/03799 Country of ref document: ZA Ref document number: 143063 Country of ref document: IL Ref document number: 1020017005929 Country of ref document: KR Ref document number: 200103799 Country of ref document: ZA Ref document number: 26600/00 Country of ref document: AU Ref document number: 2001/01324 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09830761 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: PV2001-1650 Country of ref document: CZ |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1999968778 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017005929 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999968778 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 26600/00 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: PV2001-1650 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020017005929 Country of ref document: KR |